• Increase font size
  • Default font size
  • Decrease font size

Obama administration appeals stem cell injunction

Print E-mail
By Jeremy Pelofsky for Reuters   
Wednesday, 01 September 2010 09:17

The Obama administration asked a federal judge on Tuesday to lift an injunction halting human embryonic stem cell research, saying it would irreparably harm research and cost more than 1,300 jobs.

The Justice Department also appealed against the injunction by Judge Royce Lamberth in which he ruled National Institutes of Health funding of human embryonic stem cell research violated a law called the Dickey-Wicker Amendment, which bars federal funding of work that involves destroying embryos.

The administration said Lamberth's ruling was overly broad and was having a significant negative impact on embryonic stem cell research, arguing that there was "serious doubt" Congress intended the legislation to be so encompassing.

"Numerous ongoing projects will likely not survive even a temporary gap in funds, jeopardizing both the potential benefit of the research and the hundreds of millions of dollars of taxpayer funds already invested in it," the filing said.

The Justice Department asked Lamberth to rule by September 7 on the request to lift his injunction.

Lamberth's injunction was a setback for President Barack Obama and the issue could become a theme in November elections where his fellow Democrats who control both chambers of Congress are facing tough races.

One of Obama's first acts after taking office in 2009 was to broaden federal funding of human embryonic stem cell research -- a controversial decision because some people oppose any destruction of human embryos, even for medical research.

Dr. James Sherley, a biological engineer at Boston Biomedical Research Institute, and Theresa Deisher of Washington-based AVM Biotechnology sued, saying Obama's policy violated Dickey-Wicker and harmed their own chances of getting funding for similar research not involving embryos.

Sherley and Deisher's "remote economic self-interests do not outweigh the harm the injunction will cause NIH, the hundreds of affected human embryonic stem cell researchers, and the millions of individuals who hold out hope that human embryonic stem cell research will lead to the cure for, or treatment of, their currently incurable illnesses," the Justice Department said.

The administration pointed to 24 projects up for renewed federal funding between now and the end of September and said the benefits from the research could be lost. If the projects ended, it would waste $64 million already invested, the administration said.

Overall, the injunction could put 1,300 jobs at risk, NIH Director Francis Collins said in a declaration to the court.

Earlier on Tuesday, Democratic Representative Diana DeGette said she would push to revive legislation specifically allowing federal funding of the research by the end of September.

"We need to pass legislation in September to fix this problem," she told Reuters in a telephone interview.

DeGette co-sponsored bipartisan legislation that passed both the House and Senate twice and was twice vetoed by then-President George W. Bush.

DeGette said she believed there was support in the House and Senate, as well as in both parties, to push through legislation quickly.





BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 
about 58 minutes ago VSE Wins Multiple Award Health and Information Technology Contracts; Celldex’s CDX-011 Demonstrates High Respons... http://t.co/v4b16zU0
about 2 hours ago Forehead Lift May Provide Relief for Those Who Suffer From Migraines http://t.co/1ORmbuD4
about 6 hours ago Phys Ed: Are Marathons Bad for the Heart? http://t.co/r2fuKy7k
about 7 hours ago Sleep Apnea Tied to Increased Cancer Risk - http://t.co/l4dijE4V
about 8 hours ago Day traders take on Sophisticated algorithmic trading systems http://t.co/K5t8HgK8
about 9 hours ago Choice of investing in the next blockbuster cancer drug or in the social media bubble-- which do you chose?… http://t.co/0E05zRDd
about 10 hours ago Brains of Combat Vets Exposed to Roadside Bombs Likened to Those in Athletes http://t.co/uoYocb4Y
about 11 hours ago Focus on Perifosine May Shift For AEterna Zenatis Investors: Aeterna Zentaris Inc. (AEZS) (TSX: AEZ) is an oncol... http://t.co/2ZZQbrSG

navigation

Free Phone Trade Alerts

Benzinga.com supporter Seeking Alpha Certified